Key facts
- Nura Bio’s last known valuation is $176.0M (Nov 2025).
- It has raised $141.0M; the latest was Later Stage VC in Sep 2024.
- Notable investors include Samsara BioCapital, Euclidean Capital, Sanofi Ventures, The Column Group.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Nura Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Nura Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nura Bio
Developer of transformative neuroprotective therapies designed to prevent and protect against neuronal loss and related neuroimmune dysregulation. The company's therapies specialize in the research and development of neuronal loss to preserve neurological function and restore the neuron-glia axis's function, enabling healthcare professionals to improve the nervous system's immune surveillance capacity in response to neurological injury.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2018
- Employees
- 28
- Website
- nurabio.com/
- Ownership
- Privately Held (backing)
Nura Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nura Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nura Bio in its N-PORT filings yet. We sweep new filings monthly.